Literature DB >> 2221232

Survival discriminants for differentiated thyroid cancer.

M P Cunningham1, R B Duda, W Recant, J S Chmiel, J A Sylvester, A Fremgen.   

Abstract

Since 1975, the American Cancer Society, Illinois Division, has published end results of major cancer sites drawn from patient data contributed voluntarily by hospital cancer registries throughout the state. The current study was undertaken, in part, to apprehend information regarding contested areas in the management of patients having differentiated (papillary/follicular) thyroid cancer. A total of 2,282 patients with either papillary or follicular carcinoma of the thyroid from 76 different Illinois hospitals and providing 10 years of follow-up information (life-table analysis) were retrospectively analyzed for demographic, disease, and treatment-related predictors of survival. Multivariate analysis using the Cox proportional hazards method was made for stage, age, race, sex, morphology, history of radiation exposure, presence of positive lymph nodes, initial surgical treatment, postoperative iodine 131 therapy, and replacement/suppressive thyroid hormone treatment. Statistically significant (p less than or equal to 0.05) predictors of favorable survival after thyroid cancer were low stage (I and II), young age (less than 50 years), white race, female sex, and the administration, postoperatively, of either thyroid hormone or radioactive iodine. Factors that had no influence on survival were lymph node status, choice of initial surgical treatment, and a history of prior irradiation. We suggest that where a prospective clinical trial is impracticable, a retrospective analysis of a large and detailed database, such as that available from cooperating hospital-based tumor registries, may yet provide useful insights to solutions of cancer management problems.

Entities:  

Mesh:

Year:  1990        PMID: 2221232     DOI: 10.1016/s0002-9610(05)80539-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  30 in total

1.  Analysis of age and disease status as predictors of thyroid cancer-specific mortality using the Surveillance, Epidemiology, and End Results database.

Authors:  Ryan K Orosco; Timon Hussain; Kevin T Brumund; Deborah K Oh; David C Chang; Michael Bouvet
Journal:  Thyroid       Date:  2015-01       Impact factor: 6.568

Review 2.  Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefits, and risks.

Authors:  Yasuhiro Ito; Akira Miyauchi
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

3.  Risk factors for recurrence to the lymph node in papillary thyroid carcinoma patients without preoperatively detectable lateral node metastasis: validity of prophylactic modified radical neck dissection.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-11       Impact factor: 3.352

4.  Mitochondrial DNA mutations in differentiated thyroid cancer with respect to the age factor.

Authors:  Jürgen Witte; Steffen Lehmann; Michael Wulfert; Quin Yang; Hans D Röher
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

5.  Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group.

Authors:  K D Newman; T Black; G Heller; R G Azizkhan; G W Holcomb; C Sklar; V Vlamis; G M Haase; M P La Quaglia
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

6.  Prognostic importance of histologic vascular invasion in papillary thyroid carcinoma.

Authors:  Laura Falvo; Antonio Catania; Vito D'Andrea; Antonella Marzullo; Maria Cristina Giustiniani; Enrico De Antoni
Journal:  Ann Surg       Date:  2005-04       Impact factor: 12.969

Review 7.  Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity.

Authors:  Nicholas S Andresen; John M Buatti; Hamed H Tewfik; Nitin A Pagedar; Carryn M Anderson; John M Watkins
Journal:  Eur Thyroid J       Date:  2017-03-23

Review 8.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

9.  BRAF V600E Confers Male Sex Disease-Specific Mortality Risk in Patients With Papillary Thyroid Cancer.

Authors:  Fei Wang; Shihua Zhao; Xiaopei Shen; Guangwu Zhu; Rengyun Liu; David Viola; Rossella Elisei; Efisio Puxeddu; Laura Fugazzola; Carla Colombo; Barbara Jarzab; Agnieszka Czarniecka; Alfred K Lam; Caterina Mian; Federica Vianello; Linwah Yip; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Christine J O'Neill; Mark S Sywak; Roderick Clifton-Bligh; Bela Bendlova; Vlasta Sýkorová; Yangang Wang; Mingzhao Xing
Journal:  J Clin Oncol       Date:  2018-08-02       Impact factor: 44.544

10.  Endogenous thyrotropin and triiodothyronine concentrations in individuals with thyroid cancer.

Authors:  Jacqueline Jonklaas; Hala Nsouli-Maktabi; Steven J Soldin
Journal:  Thyroid       Date:  2008-09       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.